StockNews.AI
FLGT
StockNews.AI
109 days

Fulgent Reports First Quarter 2025 Financial Results

1. Fulgent Genetics reported Q1 2025 revenue of $73.5 million with a 16% year-over-year growth. 2. Despite revenue growth, GAAP loss was $11.5 million per share at ($0.37).

Earnings
+19.07%Current Return
VS
+1.48%S&P 500
$17.2505/02 07:07 AM EDTEvent Start
$20.5405/05 07:21 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bearish?

Despite a revenue increase, the GAAP loss suggests financial instability for FLGT, reminiscent of prior downturns following similar losses.

How important is it?

Financial results, particularly those showing a GAAP loss, typically have significant influence on stock price.

Why Short Term?

The immediate loss reported could negatively affect investor sentiment, but revenue growth indicates potential for recovery in the near term.

Related Companies

TLISNOKMDGL
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o.

Related News